The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously ...
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh ...
The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...
Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...
AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback